Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 1, 2008, Pages 183-190

  Larrú, Beatriz ^a   Resino, Salvador ^a,b   Bellón, Jose M ^a   De José, M Isabel ^c   Fortuny, Claudia ^d   Navarro, M Luisa ^a   Gurbindo, M Dolores ^a   Ramos, José Ttomás ^e   Soler Palacín, Pere ^f   Léon, Juan Antonio ^g   Asensi, Manuel ^h   Mellado, M José ^c   Muñoz Fernández, M Ángeles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d Sant Joan de Déu Nursing s School University   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^h HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Immune reconstitution; Protease inhibitors; Viral suppression

Indexed keywords

FLUTICASONE; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR;

ABDOMINAL PAIN; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; CUSHING SYNDROME; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROGNOSIS; RETROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VERTICAL TRANSMISSION; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; PYRIMIDINONES; RETROSPECTIVE STUDIES; RITONAVIR; TIME FACTORS; TREATMENT OUTCOME;

EID: 37549039809     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm436     Document Type: Article

References (36)

1. Harwell JI, Obaro SK. Antiretroviral therapy for children: Substantial benefit but limited access. JAMA 2006; 296: 330-1.
2. Foster C, Lyall EG. Children with HIV: Improved mortality and morbidity with combination antiretroviral therapy. Curr Opin Infect Dis 2005; 18: 253-9.
3. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2002; 2: 93-102.
4. Hartman K, Verweel G, de Groot R et al. Detection of lipoatrophy in human immunodeficiency virus-1 infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25 427-31.
5. Calmy A, Pascual F, Ford N. HIV drug resistance. N Engl J Med 2004; 350: 2720-1.
6. Battegay M, Nuesch R, Hirschel B et al. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006; 6: 280-7.
7. Zaccarelli-Filho CA, Ono E, Machado DM et al. HIV-1-infected children on HAART: Immunologic features of three different levels of viral suppression. Cytometry B Clin Cytom 2007; 72: 14-21.
8. Resino S, Resino R, Micheloud D et al. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin Infect Dis 2006; 42: 862-9.
9. Monno L, Saracino A, Scudeller L et al. HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience. J Acquir Immune Defic Syndr 2003; 33: 439-47.
10. Vaclavikova J, Machala L, Stankova M et al. Response of HIV positive patients to the long-term salvage therapy by lopinavir/ ritonavir. J Clin Virol 2005; 33: 319-23.
11. Ramos JT, De Jose MI, Duenas J et al. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immuno-deficiency virus-1-infected children experienced with three classes of antiretrovirals. Pediatr Infect Dis J 2005; 24: 867-73.
12. Kline MW, Rugina S, Ilie M et al. Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ ritonavir-containing highly active antiretroviral therapy. Pediatrics 2007; 119: E1116-20.
13. Landay A, da Silva BA, King MS et al. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis 2007; 44: 749-54.
14. CDCP. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR CDC Surveill Summ 1994; 43: 1-10.
15. AIDSinfo. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. http://AIDSinfo.nih.gov (26 October 2006, date last accessed).
16. Ramos JT, de Jose MI, Polo R et al. Recommendations of the CEVIHP/ SEIP/AEP/PNS on antiretroviral treatment in HIV-infected children and teenagers. Enferm Infecc Microbiol Clin 2005; 23: 279-312.
17. Resino S, Gurbindo M, Bellón J et al. Predictive markers of clinical outcome in vertically HIV-1 infected infants. A prospective longitudinal study. Pediatr Res 2000; 47: 509-15.
18. Hirsch MS, Brun-Vezinet F, D'Aquila RT et al. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. JAMA 2000; 283: 2417-26.
19. Resino S, Bellón JM, Ramos JT et al. Positive virologic outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children. A prospective cohort study. J Antimicrob Chemother 2004; 54: 921-31.
20. Saez-Llorens X, Violari A, Deetz CO et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003; 22: 216-24.
21. Guillen S, Ramos JT, Resino R et al. Impact on weight and height with the use of HAART in HIV-infected children. Pediatr Infect Dis J 2007; 26: 334-8.
22. Newell ML, Patel D, Goetghebuer T et al. CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: Is it associated with age at initiation? J Infect Dis 2006; 193: 954-62.
23. Resino S, Bellon JM, Munoz-Fernandez MA. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. J Antimicrob Chemother 2006; 57: 579-82.
24. Carter RJ, Wiener J, Abrams EJ et al. Dyslipidemia among perinatally HIV-intected children enrolled in the PACTS-HOPE cohort, 1999-2004: A longitudinal analysis. J Acquir Immune Defic Syndr 2006; 41: 453-60.
25. Beregszaszi M, Dollfus C, Levine M et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-intected children. J Acquir Immune Defic Syndr 2005; 40: 161-8.
26. de Mendoza C, Valer L, Bacheler L et al. Prevalence of the HIV-1 protease mutation 147A in clinical practice and association with lopinavir resistance. AIDS 2006; 20: 1071-4.
27. Kempf DJ, Isaacson JD, King MS et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75: 7462-9.
28. Resino S, Bellón JM, Ramos JT et al. Salvage antiretroviral therapy in HIV-infected children: Advantages of lopinavir-ritonavir. Pediatr Infect Dis J 2004; 23: 923-30.
29. Jimenez JL, Resino S, Martinez-Colom A et al. Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy. J Antimicrob Chemother 2005; 56: 1081-6.
30. Chiappini E, Galli L, Tovo PA et al. Virologic, immunologic, and clinical benefits from eady combined antiretroviral therapy in infants with perinatal HIV-1 infection. AIDS 2006; 20: 207-15.
31. Soh CH, Oleske JM, Brady MT et al. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet 2003; 362: 2045-51.
32. Walker AS, Doerholt K, Sharland M et al. Response to highly active antiretroviral therapy varies with age: The UK and Ireland Collaborative HIV Paediatric Study. AIDS 2004; 18: 1915-24.
33. Verweel G, Saavedra-Lozano J, van Rossum AM et al. Initiating highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children in Europe and the United States: Comparing clinical practice to guidelines and-literature evidence. Pediatr Infect Dis J 2006; 25: 987-94.
34. Bongiovanni M, Bini T, Tordato F et al. Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: A retrospective cohort study. J Antimicrob Chemother 2003; 51: 171-4.
35. Bongiovanni M, Chiesa E, Di Biagio A et al. Use of lopinavir/ ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART. J Antimicrob Chemother 2005; 55: 1003-7.
36. Delaugerre C, Teglas JP, Treluyer JM et al. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ ritonavir. J Acquir Immune Defic Syndr 2004; 37: 1269-75.